NURS 6630 Final Exam (5 Versions, 375 Q and A,
Latest-2021) / NURS 6630N Final Exam / NURS6630
Final Exam / NURS6630N Final Exam: Walden
University | Q and A
Question 1
A psychiatric-mental health nurse practitioner (PMHNP) is reviewing the pharmacokinetic
properties of a newly prescribed medication. The provider understands that the process by
which a drug is chemically converted in the body to a more water-soluble compound for
elimination is known as:
A. Absorption
B. Distribution
C. Metabolism
D. Excretion
Correct Answer: C. Metabolism
Rationale: Metabolism (biotransformation) is the process by which the body chemically
converts a drug into a more water-soluble form to facilitate elimination. Absorption (A) refers to
the movement of a drug from the site of administration into the bloodstream. Distribution (B) is
the movement of a drug from the bloodstream to tissues and target sites. Excretion (D) is the
removal of the drug from the body, primarily through the kidneys or bile.
Question 2
A PMHNP is evaluating a patient who reports that a medication "stopped working" after several
weeks of effective treatment. The provider suspects autoinduction of hepatic enzymes. Which
medication is most commonly associated with autoinduction?
A. Fluoxetine
B. Carbamazepine
C. Sertraline
D. Lorazepam
Correct Answer: B. Carbamazepine
, Rationale: Carbamazepine is a potent inducer of cytochrome P450 enzymes, particularly
CYP3A4, and is well-known for autoinduction—meaning it induces its own metabolism, leading
to decreased plasma levels over time and potential loss of efficacy. Fluoxetine (A) and sertraline
(C) are SSRIs that inhibit CYP enzymes. Lorazepam (D) undergoes glucuronidation and does not
significantly induce hepatic enzymes.
Question 3
Which of the following statements accurately describes the concept of "therapeutic index"?
A. The ratio of the dose that produces a therapeutic effect to the dose that produces a toxic
effect
B. The time it takes for a drug to reach steady-state plasma concentration
C. The percentage of drug that reaches systemic circulation unchanged
D. The rate at which a drug is cleared from the bloodstream
Correct Answer: A. The ratio of the dose that produces a therapeutic effect to the dose
that produces a toxic effect
Rationale: The therapeutic index (TI) is the ratio of the toxic dose to the therapeutic dose
(TD50/ED50). A narrow therapeutic index means there is a small difference between
therapeutic and toxic doses (e.g., lithium, clozapine, valproate). Option B describes half-life and
steady-state. Option C describes bioavailability. Option D describes clearance.
Question 4
A PMHNP is assessing a patient with hepatic impairment who requires psychotropic medication.
Which principle should guide prescribing?
A. Standard dosing is appropriate as the liver has reserve capacity
B. Lower initial doses and slower titration are recommended
C. Renal dosing adjustments are equivalent to hepatic adjustments
D. Only PRN medications should be used
Correct Answer: B. Lower initial doses and slower titration are recommended
Rationale: Hepatic impairment reduces the liver's ability to metabolize drugs, leading to
increased plasma levels and prolonged half-lives. Therefore, lower initial doses and slower
titration are essential to avoid toxicity. Standard dosing (A) risks accumulation. Renal dosing (C)
,applies to renally cleared drugs. PRN-only use (D) does not address the need for maintenance
treatment.
Question 5
Which cytochrome P450 enzyme is responsible for the metabolism of the largest number of
psychotropic medications?
A. CYP1A2
B. CYP2D6
C. CYP3A4
D. CYP2C19
Correct Answer: C. CYP3A4
Rationale: CYP3A4 is the most abundant CYP enzyme in the liver and metabolizes
approximately 50% of all medications, including many psychotropics (e.g., alprazolam,
midazolam, quetiapine, aripiprazole). CYP2D6 (B) metabolizes many antidepressants and
antipsychotics but fewer total drugs. CYP1A2 (A) metabolizes clozapine and olanzapine.
CYP2C19 (D) metabolizes citalopram, diazepam, and others.
Question 6
A PMHNP is considering a medication that is a potent inhibitor of CYP2D6. Which of the
following medications, if co-administered, would most likely require dose reduction?
A. Lorazepam
B. Codeine
C. Lithium
D. Valproic acid
Correct Answer: B. Codeine
Rationale: Codeine is a prodrug converted to morphine by CYP2D6. A potent CYP2D6
inhibitor (e.g., fluoxetine, paroxetine, bupropion) would block this conversion, reducing
analgesic efficacy. However, the question asks about dose reduction due to inhibition—if the
inhibited enzyme normally clears the drug, levels rise. Codeine itself is a prodrug, so inhibition
reduces active metabolite. Lorazepam (A) is glucuronidated. Lithium (C) is renally cleared.
Valproic acid (D) is glucuronidated and beta-oxidized.
, Question 7
Which of the following best describes "steady-state" plasma concentration?
A. The point at which drug absorption equals drug elimination
B. The peak plasma level after a single dose
C. The time required for 50% of a drug to be eliminated
D. The minimum effective concentration of a drug
Correct Answer: A. The point at which drug absorption equals drug elimination
Rationale: Steady-state is achieved when the rate of drug administration equals the rate of
drug elimination, resulting in a consistent plasma concentration. This typically occurs after 4–5
half-lives. Option B describes Cmax. Option C describes half-life. Option D describes the
threshold for efficacy.
Question 8
A PMHNP is prescribing a medication with a half-life of 24 hours. Approximately how long will it
take to reach steady-state?
A. 24 hours
B. 2 days
C. 5 days
D. 10 days
Correct Answer: C. 5 days
Rationale: Steady-state is reached after approximately 4–5 half-lives. With a half-life of 24
hours, steady-state would be achieved in approximately 4–5 days (96–120 hours). Options A, B,
and D are incorrect calculations.
Question 9
Which of the following is a contraindication to the use of a medication that is a strong CYP1A2
inhibitor in a patient taking clozapine?
A. The combination is safe and requires no monitoring
B. It may increase clozapine levels, increasing the risk of toxicity
Latest-2021) / NURS 6630N Final Exam / NURS6630
Final Exam / NURS6630N Final Exam: Walden
University | Q and A
Question 1
A psychiatric-mental health nurse practitioner (PMHNP) is reviewing the pharmacokinetic
properties of a newly prescribed medication. The provider understands that the process by
which a drug is chemically converted in the body to a more water-soluble compound for
elimination is known as:
A. Absorption
B. Distribution
C. Metabolism
D. Excretion
Correct Answer: C. Metabolism
Rationale: Metabolism (biotransformation) is the process by which the body chemically
converts a drug into a more water-soluble form to facilitate elimination. Absorption (A) refers to
the movement of a drug from the site of administration into the bloodstream. Distribution (B) is
the movement of a drug from the bloodstream to tissues and target sites. Excretion (D) is the
removal of the drug from the body, primarily through the kidneys or bile.
Question 2
A PMHNP is evaluating a patient who reports that a medication "stopped working" after several
weeks of effective treatment. The provider suspects autoinduction of hepatic enzymes. Which
medication is most commonly associated with autoinduction?
A. Fluoxetine
B. Carbamazepine
C. Sertraline
D. Lorazepam
Correct Answer: B. Carbamazepine
, Rationale: Carbamazepine is a potent inducer of cytochrome P450 enzymes, particularly
CYP3A4, and is well-known for autoinduction—meaning it induces its own metabolism, leading
to decreased plasma levels over time and potential loss of efficacy. Fluoxetine (A) and sertraline
(C) are SSRIs that inhibit CYP enzymes. Lorazepam (D) undergoes glucuronidation and does not
significantly induce hepatic enzymes.
Question 3
Which of the following statements accurately describes the concept of "therapeutic index"?
A. The ratio of the dose that produces a therapeutic effect to the dose that produces a toxic
effect
B. The time it takes for a drug to reach steady-state plasma concentration
C. The percentage of drug that reaches systemic circulation unchanged
D. The rate at which a drug is cleared from the bloodstream
Correct Answer: A. The ratio of the dose that produces a therapeutic effect to the dose
that produces a toxic effect
Rationale: The therapeutic index (TI) is the ratio of the toxic dose to the therapeutic dose
(TD50/ED50). A narrow therapeutic index means there is a small difference between
therapeutic and toxic doses (e.g., lithium, clozapine, valproate). Option B describes half-life and
steady-state. Option C describes bioavailability. Option D describes clearance.
Question 4
A PMHNP is assessing a patient with hepatic impairment who requires psychotropic medication.
Which principle should guide prescribing?
A. Standard dosing is appropriate as the liver has reserve capacity
B. Lower initial doses and slower titration are recommended
C. Renal dosing adjustments are equivalent to hepatic adjustments
D. Only PRN medications should be used
Correct Answer: B. Lower initial doses and slower titration are recommended
Rationale: Hepatic impairment reduces the liver's ability to metabolize drugs, leading to
increased plasma levels and prolonged half-lives. Therefore, lower initial doses and slower
titration are essential to avoid toxicity. Standard dosing (A) risks accumulation. Renal dosing (C)
,applies to renally cleared drugs. PRN-only use (D) does not address the need for maintenance
treatment.
Question 5
Which cytochrome P450 enzyme is responsible for the metabolism of the largest number of
psychotropic medications?
A. CYP1A2
B. CYP2D6
C. CYP3A4
D. CYP2C19
Correct Answer: C. CYP3A4
Rationale: CYP3A4 is the most abundant CYP enzyme in the liver and metabolizes
approximately 50% of all medications, including many psychotropics (e.g., alprazolam,
midazolam, quetiapine, aripiprazole). CYP2D6 (B) metabolizes many antidepressants and
antipsychotics but fewer total drugs. CYP1A2 (A) metabolizes clozapine and olanzapine.
CYP2C19 (D) metabolizes citalopram, diazepam, and others.
Question 6
A PMHNP is considering a medication that is a potent inhibitor of CYP2D6. Which of the
following medications, if co-administered, would most likely require dose reduction?
A. Lorazepam
B. Codeine
C. Lithium
D. Valproic acid
Correct Answer: B. Codeine
Rationale: Codeine is a prodrug converted to morphine by CYP2D6. A potent CYP2D6
inhibitor (e.g., fluoxetine, paroxetine, bupropion) would block this conversion, reducing
analgesic efficacy. However, the question asks about dose reduction due to inhibition—if the
inhibited enzyme normally clears the drug, levels rise. Codeine itself is a prodrug, so inhibition
reduces active metabolite. Lorazepam (A) is glucuronidated. Lithium (C) is renally cleared.
Valproic acid (D) is glucuronidated and beta-oxidized.
, Question 7
Which of the following best describes "steady-state" plasma concentration?
A. The point at which drug absorption equals drug elimination
B. The peak plasma level after a single dose
C. The time required for 50% of a drug to be eliminated
D. The minimum effective concentration of a drug
Correct Answer: A. The point at which drug absorption equals drug elimination
Rationale: Steady-state is achieved when the rate of drug administration equals the rate of
drug elimination, resulting in a consistent plasma concentration. This typically occurs after 4–5
half-lives. Option B describes Cmax. Option C describes half-life. Option D describes the
threshold for efficacy.
Question 8
A PMHNP is prescribing a medication with a half-life of 24 hours. Approximately how long will it
take to reach steady-state?
A. 24 hours
B. 2 days
C. 5 days
D. 10 days
Correct Answer: C. 5 days
Rationale: Steady-state is reached after approximately 4–5 half-lives. With a half-life of 24
hours, steady-state would be achieved in approximately 4–5 days (96–120 hours). Options A, B,
and D are incorrect calculations.
Question 9
Which of the following is a contraindication to the use of a medication that is a strong CYP1A2
inhibitor in a patient taking clozapine?
A. The combination is safe and requires no monitoring
B. It may increase clozapine levels, increasing the risk of toxicity
